The blockbuster $6bn sale of distribution monolith Ingram Micro has been cleared by US antitrust officials, clearing perhaps the most treacherous obstacle standing in the way of the deal’s approval.
The Committee on Foreign Investment in the United States has given the go-ahead to both parties for the sale of the world’s largest IT distributor to Chinese conglomerate Tianjin Tianhai, announced in February.
The transaction was also approved by anti-trust authorities in Austria, Italy, Poland and Slovakia.
The merger’s completion remains subject to approval from China’s State Administration of Foreign Exchange in addition to other customary closing conditions, but Ingram Micro claims that the transaction is still expected to close in 2016.
Ingram’s sale has seen its fair share of bumps in the road during its approval process. A little more than a month after the deal was announced, the broadliner’s shareholders sued Ingram over the “grossly inadequate” sale price, and in July the Shanghai Stock Exchange delayed the transaction’s approval and raised questions about Ingram’s credit rating and finances.
Full Content: Channel Web
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas